Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
EBioMedicine 49:318330
However, the robustness of the evidence differs markedly: data are extensive for obesity, more limited and heterogeneous for BED, and extremely sparse for BN
Beyond routine glucose and lipid panels, endocrine studies increasingly include microbiome profiling, bile-acid pools, and hepatokine/adipokine panels (FGF21, adiponectin) to explain shifts in substrate preference
This encompasses individuals with obesity, T2DM, and NAFLD, many of whom can have multiple comorbidities
The more options people have, the better, says Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine
US$ 20.08
US$ 24.69
US$ 21.85
US$ 20.77
US$ 23.00
US$ 24.59
US$ 21.41
US$ 21.07
